ROBOTIC RADICAL HYSTERECTOMY (RRH) VERSUS CHEMO-RADIATION (CRT) FOLLOWED BY TYPE 1 ROBOTIC HYSTERECTOMY FOR 1B2 CERVICAL CANCER (CC)

<u>Christine K. Fitzsimmons, DO;</u> Amanda J. Stephens, DO; Jessica A. Kennard, DO; Madhavi Manyam, DO; Julie W. Pepe, PhD; Kayla M. DeCoff, BS; Sarfraz Ahmad, PhD; Nathalie D. McKenzie, MD; James E. Kendrick, MD; Robert W. Holloway, MD

Gynecologic Oncology Program, AdventHealth Cancer Institute, Orlando, FL 32804, USA

Abstract


Objectives: To compare perioperative outcomes, RFS, and OS for patients with FIGO 2014 stage 1B2 CC treated by RRH versus CRT and brachytherapy (BT) followed by Type 1 robotic hysterectomy (RH). **Methods:** Patients with FIGO 2014 stage 1B2 CC (1/2007-12/2017) who underwent RRH (Group A) or CRT and VB followed by RH (Group B) were identified. Inclusion criteria included: adenocarcinoma or squamous cell histology; > 12 month follow-up, tumor size (TS) >4 cm by either pathology in A or radiographic / clinical criteria in B, and no evidence of para-aortic node metastasis on imaging.

<u>Results</u>: 15 group A (median TS=5.0±1.2 cm) and 31 group B (median TS=5.0±1.0 cm) patients were identified. Pre-operative imaging reported no positive nodes in A compared to 8 (25%) in B. 12 (80%) required postoperative adjuvant CRT in group A. Median follow up was 64±34.6 months for A versus 33±32.7 months for B (*p*=0.059). No (+)para-aortic nodes were identified in A versus 5 cases in B (*p*=0.15). Recurrences were diagnosed in 3 (20%) A and 7 (22.5%) B cases. Median time to recurrence was 15±49 months for A compared to 11±7 months in B. 5-year RFS and OS was 80% & 84.7% (A) versus 78% & 83.9% (B) [*p*>0.05]. Complications included major urinary fistula (n=3;20%) and cuff dehiscence (n=1;6.7%) in A versus one each for B (3.3%).

Conclusions: Despite having higher risk factors of para-aortic metastasis, patients with IB2 CC treated with CRT/BT/RH had similar RFS/OS to RRH, and with less fistulae and cuff dehiscence.

Introduction

- Using the new FIGO 2018 guidelines, Stage 1B2 tumors may be treated with either:
 - Primary surgical treatment: RH / Pelvic / Para-aortic lymphadenectomy
 - Definitive CRT and BT
 - Can consider CRT / BT followed by adjuvant type 1 hysterectomy²
- A recent study by Landoni et al¹ showed that the 20 year survival was similar between upfront surgery versus definitive radiotherapy in Stage IB-IIA cervical cancers
- Adjuvant radiation following radical hysterectomy increases the risk of morbidity¹



Demographics and Results

	Group A (RRH), N=15	Group B (CRT/VB/RH), N=31	<i>p</i> -Value
Age	49 ± 14 years	47 ±11 years	NS
BMI	26.7 ±5.6	27.9 ±6.6	NS
Pre-operative Radiologic Pelvic Nodes Positive	0% (N=0)	29% (N=9)	<0.001
Surgery Time	184 ±53 minutes	128 ±32 minutes	<0.001
Estimated Blood Loss	106 ±78 cc	68 ± 42 cc	NS
Transfusion Rate	0% (N=0)	3.3% (N=1)	NS

Pathology

Characteristic	Group A (RRH), N= 15	Group B (CRT/VB/RH), N= 31	<i>p</i> -Value		
TS (cm)	5±1.8	5±1.0	NS		
LVSI	60% (N=9)	14% (N=4*) * Post CRT	<0.001		
Adenocarcinoma	53% (N=8)	45% (N=14)	NS		
(+) Pelvic Nodes	30% (N=3)	16% (N=5*)	NS		
Para-aortic Nodes Sampled	26.6% (N=4)	100% (N=31)	NS		
(+) Para-aortic Nodes	0	16% (N=5)	0.15		
(+) Vaginal Margins	20% (N=3)	0	NS		
(+) Parametria	14.3% (N=2)	22.5% (N=7)	NS		
Recurrence, Survival, Complications Data					
Recurrence, Survival, C	omplications	Data			
Recurrence, Survival, C	Group A (RRH), N= 15	Data Group B (CRT/VB/RH), N= 31	<i>P</i> -Value		
Recurrence, Survival, C	Group A	Group B	P-Value NS		
	Group A (RRH), N= 15	Group B (CRT/VB/RH), N= 31			
Recurrence Rate	Group A (RRH), N= 15 20% (N=3)	Group B (CRT/VB/RH), N= 31 22.5% (N=7)	NS		
Recurrence Rate Distant Recurrence	Group A (RRH), N= 15 20% (N=3) 33.3% (N =1)	Group B (CRT/VB/RH), N= 31 22.5% (N=7) 71.4% (N =5)	NS NS		
Recurrence Rate Distant Recurrence Median Time to Recurrence	Group A (RRH), N= 15 20% (N=3) 33.3% (N =1) 15±49 months	Group B (CRT/VB/RH), N= 31 22.5% (N=7) 71.4% (N =5) 11±7 months	NS NS NS		
Recurrence Rate Distant Recurrence Median Time to Recurrence 5-year DFS	Group A (RRH), N= 15 20% (N=3) 33.3% (N =1) 15±49 months 80.0%	Group B (CRT/VB/RH), N= 31 22.5% (N=7) 71.4% (N =5) 11±7 months 78%	NS NS NS NS		
Recurrence Rate Distant Recurrence Median Time to Recurrence 5-year DFS 5-year OS	Group A (RRH), N= 15 20% (N=3) 33.3% (N =1) 15±49 months 80.0% 84.7%	Group B (CRT/VB/RH), N= 31 22.5% (N=7) 71.4% (N =5) 11±7 months 78% 83.9%	NS NS NS NS NS		

- The RetroEMBRACE study for primary RT, included all locally advanced cervical cancer, reported an overall pelvic control of 91% [all stages]; and in stage IB (substages not reported) patients of 98% at 5-years⁴
- Previous CRT followed by open simple hysterectomy study by Bigsby et al (n=69) showed: 81% 5-year survival rate, 97% local control rate, 0% subsequent pelvic exenteration, and 4.3% vaginal stenosis.³

Objectives

- To evaluate the safety and efficacy of robotic assisted laparoscopic simple hysterectomy with para-aortic lymphadenectomy after chemoradiation and limited brachytherapy
- Compare surgical and oncologic outcomes between occult 1B2 patients following robotic radical hysterectomy and known 1B2 patients treated with chemoradiation/limited brachytherapy followed by robotic hysterectomy/staging para-aortic lymphadenectomy

Materials and Methods

- Patients with FIGO 2014 stage 1B2 CC (1/2007-12/2017) who underwent RRH (Group A) or CRT and VB followed by RH (Group B) were identified
- Inclusion criteria included:
 - Adenocarcinoma or Squamous cell histology
 - > 12 month follow-up
 - Tumor size (TS) > 4 cm by either pathology in Group A or radiographic / clinical criteria in Group B
 - No evidence of para-aortic node metastasis on imaging in groups A or B
 - Group B included positive pelvic nodes utilizing radiographic criteria pre-operatively

Conclusions

- Despite a 16% rate of para-aortic metastasis and 29% radiographic positive pelvic nodes, patients with IB2 CC treated with CRT/BT/RH had similar RFS / OS to RRH
- Overall operating time was less in CRT/BT/RH compared with RRH
- CRT/BT/RH overall had fewer complications (fistulae and cuff dehiscence) compared to primary RRH for 1B2 CC (FIGO 2014)
- No central failures occurred and no pelvic exenterations were performed

References

- 1. Landoni F, Colombo A, Miliani R, et al. Randomized study between radical surgery and radiotherapy for the treatment of stage IB-IIA cervical cancer: 20-year update. *J. Gynecol. Oncol.* 2017; 28 (3); e34. doi: 10.3802/jgo.2017.28.e34.
- P. NCCN Guidelines- Cervical Cancer, 2019.
- 3. Bigsby GE, Holloway RW, Ahmad S, et al. Chemoradiation with adjuvant hysterectomy for stage IB-2 cervical cancer: A 10 year experience. *Gynecol. Surg.* 2012; 9: 327-333.
- 4. Sturdza A, Potter R, Fokdal LU, et al. Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE: A multicenter cohort study. *Radiother. Oncol.* 2016; 120: 428-433.



International Gynecologic Cancer Society Global Meeting 2019